$2.29
Live
1.66%
Downside
Day's Volatility :2.09%
Upside
0.43%
7.81%
Downside
52 Weeks Volatility :38.99%
Upside
33.82%
Period | Aytu Biopharma Inc | Index (Russel 2000) |
---|---|---|
3 Months | -16.83% | 0.0% |
6 Months | -18.5% | 0.0% |
1 Year | -22.11% | 0.0% |
3 Years | -95.53% | -23.0% |
Market Capitalization | 14.1M |
Book Value | $4.64 |
Earnings Per Share (EPS) | -2.86 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.0 |
Profit Margin | -19.56% |
Operating Margin TTM | -4.45% |
Return On Assets TTM | -1.06% |
Return On Equity TTM | -47.24% |
Revenue TTM | 81.0M |
Revenue Per Share TTM | 14.63 |
Quarterly Revenue Growth YOY | -41.5% |
Gross Profit TTM | 66.6M |
EBITDA | 6.1M |
Diluted Eps TTM | -2.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.49 |
EPS Estimate Next Year | 0.65 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 249.34%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.3M | ↑ 100.01% |
Net Income | -47.2M | ↑ 362.97% |
Net Profit Margin | -644.33% | ↓ 365.97% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 27.6M | ↑ 277.47% |
Net Income | -3.7M | ↓ 92.16% |
Net Profit Margin | -13.39% | ↑ 630.94% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 65.6M | ↑ 137.52% |
Net Income | -58.3M | ↑ 1475.55% |
Net Profit Margin | -88.81% | ↓ 75.42% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 96.7M | ↑ 47.29% |
Net Income | -108.8M | ↑ 86.62% |
Net Profit Margin | -112.53% | ↓ 23.72% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 107.4M | ↑ 11.1% |
Net Income | -17.1M | ↓ 84.33% |
Net Profit Margin | -15.88% | ↑ 96.65% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 81.0M | ↓ 24.58% |
Net Income | -15.8M | ↓ 7.1% |
Net Profit Margin | -19.56% | ↓ 3.68% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.7M | ↓ 13.49% |
Net Income | -5.8M | ↓ 43.77% |
Net Profit Margin | -25.7% | ↑ 13.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.7M | ↑ 35.19% |
Net Income | -2.5M | ↓ 57.94% |
Net Profit Margin | -7.99% | ↑ 17.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.1M | ↓ 28.09% |
Net Income | -8.1M | ↑ 230.48% |
Net Profit Margin | -36.74% | ↓ 28.75% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.9M | ↑ 3.78% |
Net Income | -220.0K | ↓ 97.29% |
Net Profit Margin | -0.96% | ↑ 35.78% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 18.0M | ↓ 21.54% |
Net Income | -2.9M | ↑ 1213.64% |
Net Profit Margin | -16.06% | ↓ 15.1% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 18.0M | ↓ 0.09% |
Net Income | -4.6M | ↑ 59.86% |
Net Profit Margin | -25.7% | ↓ 9.64% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 34.7M | ↑ 64.87% |
Total Liabilities | 27.6M | ↑ 261.9% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 152.8M | ↑ 340.18% |
Total Liabilities | 57.8M | ↑ 109.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 265.7M | ↑ 73.83% |
Total Liabilities | 128.1M | ↑ 121.55% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 137.6M | ↓ 48.2% |
Total Liabilities | 91.5M | ↓ 28.55% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 136.5M | ↓ 0.84% |
Total Liabilities | 97.1M | ↑ 6.09% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 118.1M | ↓ 13.46% |
Total Liabilities | 90.4M | ↓ 6.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 147.2M | ↑ 4.09% |
Total Liabilities | 106.3M | ↑ 11.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 136.5M | ↓ 7.3% |
Total Liabilities | 97.1M | ↓ 8.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 132.9M | ↓ 2.62% |
Total Liabilities | 100.7M | ↑ 3.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 131.2M | ↓ 1.23% |
Total Liabilities | 98.4M | ↓ 2.31% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 128.9M | ↓ 1.82% |
Total Liabilities | 98.1M | ↓ 0.32% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 118.1M | ↓ 8.36% |
Total Liabilities | 90.4M | ↓ 7.86% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.8M | ↓ 13.23% |
Investing Cash Flow | -1.1M | ↑ 119.29% |
Financing Cash Flow | 19.1M | ↓ 15.82% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.4M | ↑ 105.14% |
Investing Cash Flow | -5.7M | ↑ 432.57% |
Financing Cash Flow | 71.1M | ↑ 272.57% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.0M | ↓ 8.49% |
Investing Cash Flow | -2.8M | ↓ 50.81% |
Financing Cash Flow | 30.3M | ↓ 57.35% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.8M | ↑ 11.01% |
Investing Cash Flow | -3.2M | ↑ 16.75% |
Financing Cash Flow | 1.5M | ↓ 94.95% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↓ 82.21% |
Investing Cash Flow | -117.0K | ↓ 96.4% |
Financing Cash Flow | 8.9M | ↑ 479.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↑ 19.1% |
Investing Cash Flow | -155.0K | ↑ 3000.0% |
Financing Cash Flow | 2.6M | ↓ 238.5% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.4M | ↓ 422.26% |
Investing Cash Flow | -155.0K | ↑ 0.0% |
Financing Cash Flow | -5.4M | ↓ 309.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -211.0K | ↓ 102.25% |
Investing Cash Flow | -76.0K | ↓ 50.97% |
Financing Cash Flow | -2.7M | ↓ 49.41% |
Sell
Neutral
Buy
Aytu Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Aytu Biopharma Inc | -3.78% | -18.5% | -22.11% | -95.53% | -98.99% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Aytu Biopharma Inc | NA | NA | 0.0 | -2.49 | -0.47 | -0.01 | NA | 4.64 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Aytu Biopharma Inc | Buy | $14.1M | -98.99% | NA | -19.56% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Aytu Biopharma Inc
Revenue is down for the last 3 quarters, 22.93M → 17.97M (in $), with an average decrease of 10.8% per quarter
Netprofit is down for the last 3 quarters, -220.0K → -4.62M (in $), with an average decrease of 636.8% per quarter
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 70.1%
In the last 3 years, Aytu Biopharma Inc has experienced a drawdown of -95.5%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 41.1%
Nantahala Capital Management, LLC
Stonepine Capital Management Llc
Armistice Capital, LLC
Renaissance Technologies Corp
Geode Capital Management, LLC
Vanguard Group Inc
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
Organization | Aytu Biopharma Inc |
Employees | 102 |
CEO | Mr. Joshua R. Disbrow |
Industry | Consumer Services |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.29
+0.0%
Invesco Bulletshares 2025 Hi
$2.29
+0.0%
Schwab International Dividend Equity Etf
$2.29
+0.0%
Blockchain Coinvestors Acquisition Corp.
$2.29
+0.0%
Allgiant Travel Company
$2.29
+0.0%
Rogers Corp
$2.29
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.29
+0.0%
Iheartmedia
$2.29
+0.0%
Lightpath Technologies Inc
$2.29
+0.0%